Tracking down response and resistance to TRK inhibitors

Abstract

Two recent studies validate the LMNA–NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA–NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker–based clinical trials across cancer subtypes.